FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and may be used for improving rheological properties of sputum and inhibiting the bacterial biofilm formation in bronchi in treating cystic fibrosis. That is ensured by using recombinant human deoxyribonuclease-1 covalently bond to homopolymeric polysaccharide containing 80 links of alpha-2,8 sialic acid as an inhalation agent. There are also presented a method and administration of a drug preparation for improving the rheological properties of sputum.
EFFECT: group of inventions enables maintaining a higher level of DNA-hydrolytic activity of the administered drug preparation in bronchial mucus.
3 cl, 3 dwg, 4 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| INHALATION DRUG FORM OF POLYSIALYLATED HUMAN DOEXYRIBONUCLEASE I AND METHOD OF OBTAINING THEREOF | 2010 |
|
RU2559522C2 |
| PHARMACEUTICAL COMPOSITION FOR IMPROVING RHEOLOGICAL PROPERTIES OF SPUTUM BASED ON ENZYME NUCLEASE SERRATIA MARCESCENS | 2018 |
|
RU2695132C1 |
| HUMAN OXYNTOMODULIN, ITS APPLICATION, MEDICATION BASED THEREON AND METHOD OF APPLYING MEDICATION FOR TREATMENT AND PREVENTION OF HYPERGLYCEMIA | 2009 |
|
RU2524204C2 |
| ALDEHYDE DERIVATIVES OF SIALIC ACID, METHODS OF THEIR OBTAINMENT, CONJUGATES OF ALDEHYDE DERIVATIVES OF SIALIC ACID, AND PHARMACEUTICAL COMPOSITION BASED ON THEM | 2004 |
|
RU2333223C2 |
| METHOD OF REDUCING CONTENT OF ENDOTOXIN IN SAMPLE CONTAINING POLYSIALIC ACID AND ENDOTOXIN | 2008 |
|
RU2473567C2 |
| N-TAILED POLYSIALYLATION | 2007 |
|
RU2432175C2 |
| COMPLEX OF BIOLOGICALLY ACTIVE RECOMBINANT PROTEIN WITH POLYSIALIC ACID | 2008 |
|
RU2391354C1 |
| POLYSIALIC ACID DERIVATIVES | 2004 |
|
RU2327703C2 |
| GLYCOPOLYSIALYLATION OF PROTEINS, WHICH ARE NOT BLOOD CLOTTING PROTEINS | 2010 |
|
RU2533619C2 |
| GLYCOPOLYSIALYLATION OF PROTEINS THAT ARE NOT THE PROTEINS OF THE BLOOD CLOTTING | 2014 |
|
RU2662807C2 |
